Vir Biotechnology

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vir Biotechnology reports Q2 results, focuses on breakthrough therapies

Vir Biotechnology's Q2 2023 performance reflects strong financial discipline and a focus on advancing breakthrough therapies for infectious diseases.
Despite challenges in trial outcomes and treatment durations, Vir's robust cash position and diverse pipeline position it well for future growth.
The company's strategic strengths in capitalization, pipeline diversity, and commitment to medical innovation present promising opportunities for continued success.

Vir Biotechnology reports Q3 loss, eyes growth in diverse sectors

Vir Biotechnology's Q3 2023 performance reflected revenue decline, high R&D expenses, and a consolidated net loss, offset by strong financial position.
Strengths include a robust financial standing, advancements in next-generation antibodies, and application of trial learnings to enhance analysis.
Challenges encompass expansion into new sectors, regulatory criteria, and dose calibration, while opportunities exist in HIV programs and strategic expansions.
Overall, Vir Biotechnology navigates financial challenges with a focus on innovation and growth in diverse therapeutic areas.

Vir Biotechnology advances hepatitis treatments amidst financial growth and challenges

Vir Biotechnology's Q4 2023 performance reflects progress in drug development for hepatitis delta, hepatitis B, and HIV, supported by a strong financial position.
While facing challenges such as leadership transitions and pipeline restructuring, the company remains focused on clinical trial enrollment and cost management.
Opportunities lie in sharing trial data, expanding treatment regimens, and collaborating for improved disease management, positioning Vir for future growth and innovation.
Strategic allocation of resources and a commitment to advancing therapeutic solutions underscore Vir's resilience and potential for long-term success in the biopharmaceutical industry.

Vir Biotechnology excels in Q1 trials, eyes transformative growth

Vir Biotechnology's Q1 performance reflects progress in clinical trials and strategic initiatives, positioning the company for transformative growth in 2024.
Despite leadership changes and regulatory challenges, Vir Biotechnology's strong pipeline and global study designs offer resilience and potential for market success.
The upcoming data presentations and trial milestones present key opportunities for Vir Biotechnology to solidify its position in the biopharmaceutical industry and drive shareholder value.

Vir Biotechnology reports breakthrough results in hepatitis delta treatment

Vir Biotechnology's Q3 2024 earnings call highlighted promising results from the SOLSTICE trial in chronic hepatitis delta and strategic collaborations with Sanofi.
The company's financial performance and pipeline updates demonstrate a strong foundation for growth and innovation in the biopharmaceutical industry.
While facing challenges in regulatory complexities and financial management, Vir Biotechnology remains well-positioned to capitalize on opportunities in transformative therapies.
Overall, Vir's focus on advancing hepatitis programs and T-cell engagers underscores a commitment to addressing critical medical needs and driving shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

News that the two biotechs are working together on monoclonal antibody treatments for the coronavirus has excited investors.

Vir Biotechnology and WuXi Biologics to Collaborate on COVID-19 Treatment

The company announced a partnership in its efforts to develop monoclonal antibodies capable of neutralizing the novel coronavirus strain.

Here's Why Vir Biotechnology Rose as Much as 100.1% Today

SAN FRANCISCO and SHANGHAI, China, Feb.  25, 2020  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and WuXi Biologics (stock code: 2269.HK) today announced a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential treatment of COVID-19 (Coronavirus Disease 2019), a disease caused by SARS-CoV-2.

Vir Biotechnology and WuXi Biologics Announce Collaboration for Global Development of Antibodies to Treat COVID-19

Antibody-based treatments can be used both to protect people from infection and to treat those already affected.

Vir Bio Identifies 2 Antibodies That Might Stop Coronavirus

SAN FRANCISCO, Feb.  12, 2020  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, today announced that it has identified two monoclonal antibodies (mAbs) that bind to SARS-CoV-2 (previously known as “2019-nCoV”), which were originally found because they bind and neutralize the original SARS-CoV. The antibodies target the SARS-CoV-2 spike protein in the region that the virus uses to enter cells through the cellular receptor ACE2. Infection with SARS-CoV-2 causes the newly named disease, Covid-19.

Vir Biotechnology Identifies Two Antibodies That Bind to the Spike Protein of 2019-nCoV, Newly Named as SARS-CoV-2

Inovio Pharmaceuticals

Gilead Sciences may be winning the race to develop the first coronavirus treatment.

Here's Why Inovio Pharmaceuticals and Vir Biotechnology Shares Have Fallen Today

Moderna

Novavax

Regeneron Pharmaceuticals

Some biotech firms have been outperforming the market over the past few weeks on their treatment initiatives.

Investors rush into biotechs working on coronavirus vaccine

Allied Healthcare Products

Alpha Pro Tech

BioCryst Pharmaceuticals

Cerus

Co-Diagnostics

Dyadic International Inc., DE

Lakeland Industries

NanoViricides

Monday morning brought a huge sell-off in the market as more and more people are concerned about the growing impact of this new coronavirus.

12 Stocks Surging That Could Help Treat or Fight Coronavirus

Several public and private organizations are coming forward to develop vaccines for the new coronavirus by funding developmental programs.

CEPI Grant, Government Aid Drive Coronavirus Focused Biotechs

Here we discuss three biotech stocks, which are likely to benefit in case there is an outbreak of coronavirus infection in China.

3 Biotech Stocks Likely to Gain as Coronavirus Spreads

Aethlon Medical

AstraZeneca

Cleveland BioLabs

Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter.

13 Coronavirus-Related Stocks To Watch Amid Wuhan Outbreak

Shares of Vir Biotechnology Inc (NASDAQ: VIR), which went public in October, are poised to trade sharply higher after the San Francisco-based company announced a multi-pronged strategy for tacking the deadly coronavirus that originated in the Wuhan province of China and has spread panic wave across the globe on a possible contagion.

Vir Biotech 'Aggressively Working' On Potential Wuhan Coronavirus Treatment

SAN FRANCISCO, Jan.  22, 2020  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, is issuing the following in response to inquires from multiple academic, government, investor, and media stakeholders.

Vir Biotechnology applying multiple platforms to address public heath risk from Wuhan coronavirus

SAN FRANCISCO, Jan.  22, 2020  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, is issuing the following in response to inquiries from multiple academic, government, investor, and media stakeholders.

Vir Biotechnology applying multiple platforms to address public health risk from Wuhan coronavirus

Vir Biotechnology Is Undervalued

The stock of Vir Biotechnology lost 30% of its value on its first day of trading.

Why Did the Market Whack This IPO?

News for Vir Biotechnology Stock (VIR)